This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Brief report
Lee Hong Nien
University of Malaya Medical Centre
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1877-1722
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Iridocorneal endothelial syndrome (ICE) is a rare disease which happens usually in women at 20-40 years of age. About 50% of patient with such disease develops glaucoma.
Case presentation A 29-year-old woman presented in August 2015 with right eye blurring of vision for 6 months. On examination, the corneal endothelial with beaten metal appearance was noted. Right eye correctopia with iris atrophy and periphery anterior synechiae were seen. Mottled appearance of the macula which tallied with the optical coherence tomography (OCT) findings of cystoid macular edema (CME) was found. An non-steroidal anti-inflammatory drugs (NSAIDs) eye drops (NEVANACÒ Nepafenac ophthalmic suspension 0.1%) was commenced for long term. She was re-examined 2 years later in 2018. Her vision was 6/6. OCT and fundus fluorescence angiography (FFA) finding were normal.
Conclusion The NSAIDs was the only treatment received by the patient and throughout the years, her CME has subsided. A long term use of Nepafenac 0.1% has shown to be effective in treating CME in ICE syndrome.
Keywords
Iridocorneal endothelial syndrome (ICE), non-steroidal anti-inflammatory drugs (NSAIDs), cystoid macular edema (CME)
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 09 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Ophthalmology
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Brief report
Lee Hong Nien
University of Malaya Medical Centre
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1877-1722
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 09 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Ophthalmology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Iridocorneal endothelial syndrome (ICE) is a rare disease which happens usually in women at 20-40 years of age. About 50% of patient with such disease develops glaucoma.
Case presentation A 29-year-old woman presented in August 2015 with right eye blurring of vision for 6 months. On examination, the corneal endothelial with beaten metal appearance was noted. Right eye correctopia with iris atrophy and periphery anterior synechiae were seen. Mottled appearance of the macula which tallied with the optical coherence tomography (OCT) findings of cystoid macular edema (CME) was found. An non-steroidal anti-inflammatory drugs (NSAIDs) eye drops (NEVANACÒ Nepafenac ophthalmic suspension 0.1%) was commenced for long term. She was re-examined 2 years later in 2018. Her vision was 6/6. OCT and fundus fluorescence angiography (FFA) finding were normal.
Conclusion The NSAIDs was the only treatment received by the patient and throughout the years, her CME has subsided. A long term use of Nepafenac 0.1% has shown to be effective in treating CME in ICE syndrome.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Loading...